Schrodinger, Inc. revenue by segment SDGR

Annual Quarterly

Schrodinger, Inc. splits its revenue 2 ways in its filings. By operating segments, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Software at $40.2 million, 62% of the total. By sales mix, the largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Drug Discovery at $24.2 million, 38% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Sep 30, 2026	Q3 FY2026 Sep 30, 2026	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024
Revenue	269	64	59	59	87	54	55	60	88
Operating segments
Software	181 -14.0% share 67.1%	40 -1.5% share 62.4%	35 -12.5% share 60.2%	36 -27.2% share 60.7%	69 -13.0% share 79.4%	41 share 75.2%	41 share 74.0%	49 share 82.0%	80 share 90.2%
Drug Discovery	89 +88.3% share 32.9%	24 +80.1% share 37.6%	23 +64.8% share 39.8%	23 +114.5% share 39.3%	18 +107.4% share 20.6%	13 share 24.8%	14 share 26.0%	11 share 18.0%	9 share 9.8%
Sales mix
Drug Discovery	—	24 +85.9% share 37.5%	23 share 39.0%	23 +123.5% share 39.1%	18 +107.4% share 20.6%	13 share 23.9%	—	10 share 17.2%	9 share 9.8%
Hosted Software	—	17 +48.8% share 26.7%	15 +36.1% share 25.7%	12 +11.1% share 20.6%	12 +3.2% share 13.2%	12 share 21.3%	11 share 20.3%	11 share 18.3%	11 share 12.7%
On Premise Software	—	13 -16.1% share 20.7%	9 -40.9% share 15.8%	14 share 24.2%	44 -19.9% share 50.8%	16 share 29.3%	16 share 28.7%	—	55 share 62.7%
Maintenance	—	5 -33.1% share 7.1%	5 -28.0% share 8.3%	7 share 11.4%	7 +17.1% share 7.9%	7 share 12.6%	7 share 12.4%	—	6 share 6.7%
Professional Services	—	3 +87.1% share 4.6%	3 +35.1% share 5.5%	3 +40.2% share 4.5%	4 +64.0% share 4.4%	2 share 2.9%	2 share 4.3%	2 share 3.2%	2 share 2.6%
Contribution	—	2 -60.1% share 3.3%	3 -29.8% share 5.7%	0 -96.6% share 0.3%	—	5 share 9.9%	5 share 8.7%	4 share 7.3%	—
Drug Discovery Contribution	—	0 -86.2% share 0.1%	0 +59.3% share 0.7%	0 -70.3% share 0.3%	—	0 share 0.8%	0 share 0.5%	0 share 0.8%	—

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Pharmaceutical Preparations (SIC 2834)
Listed as: SDGR (Nasdaq)
Fiscal year ends: December 31
Incorporated in: DE
Headquarters: New York, NY
SEC filer status: Large accelerated filer
SEC CIK: 1490978

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.